Biotoscana Investments SA (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced its financial results for 2018 on Friday.
The company reported an increase in net revenue for 2018 of 10% in constant currency, positively impacted by its Dosa drug, marking BRL821m.
The firm posted net income at BRL63m in 2018 compared with BRL17m in 2017.
Gross profit increased by 12% vs 2017, in constant currency.
Gross margin of 51% (including hyperinflation adjustments) vs 54% in 2017.
OPEX are in line with 34% of net revenues in 2018.
(1USD=4BRL)
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva